Abstract
To confirm the postmarketing safety and efficacy of Emdogain® in daily use, we conducted a 3-year survey based on Japanese reexamination by Seikagaku Corporation, an importer.
We analyzed 956 cases from 171 dental clinics, including 8 university hospitals, throughout Japan. The survey was done at surgery using Emdogain® and 8 month postoperatively. Adverse reaction, change in pocket depth, improvement in bleeding on probing and tooth mobility, change in clinical attachment, and improvement in bone defect, furcation, and overall assessment were evaluated.
No adverse reactions related to Emdogain® were reported. Significant reduction in pocket depth (about 4 mm), significant improvement in bleeding on probing and tooth mobility, gain in clinical attachment, and improvement in bone defect, furcation, and overall assessment were observed at evaluation 8 month postoperatively.
We confirmed that Emdogain® is safe and useful in guided tissue regeneration in periodontal diseases.
